Biological Evaluations and Computer-Aided Approaches of Janus Kinases 2 and 3 Inhibitors for Cancer Treatment: A Review

• Váldodahkkit: Lenci K. Vázquez-Jiménez (Dahkki), Gildardo Rivera (Dahkki), Alfredo Juárez-Saldivar (Dahkki), Jessica L. Ortega-Balleza (Dahkki), Eyra Ortiz-Pérez (Dahkki), Elena Jaime-Sánchez (Dahkki), Alma Paz-González (Dahkki), Edgar E. Lara-Ramírez (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2024-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Cancer remains one of the leading diseases of mortality worldwide. Janus kinases 2/3 (JAK2/3) have been considered a drug target for the development of drugs to treat different types of cancer. JAK2/3 play a critical role in innate immunity, inflammation, and hematopoiesis by mediating the signaling...